Skip to main content

Table 5 Cost, outcomes and incremental cost effectiveness ratio for combination therapy compared with dutasteride monotherapy

From: A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

10-year horizon Total cost US$ Total QALYs Incremental costs Incremental QALYs Incremental cost per QALY gained
 Fixed dose therapy 1450279504.76 18836849.43 594535937.61 401192.00 1481.92
 Dutasteride 855743567.15 18435657.43    
15-year horizon      
 Combination 2194123563.22 23890352.46 852086147.24 938291.33 908.13
 Dutasteride 1578867548.20 20879011.27